Aurobindo Pharma Recalls Gabapentin Capsules Due to Empty Capsule Complaints
Aurobindo Pharma USA Inc is recalling 24,816 bottles of Gabapentin 300 mg capsules nationwide because of complaints that the capsules were empty.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II and involves a quality control issue (empty capsules) rather than a high-risk pathogen or structural defect, fitting the criteria for moderate severity involving minor labeling or quality errors.
Plain-English summary
Aurobindo Pharma USA Inc is recalling 24,816 bottles of Gabapentin Capsules, USP 300 mg, 100-count bottles. The product is a prescription-only medication manufactured for Northstar Rx LLC and manufactured by Aurobindo Pharma Limited in India. The specific lot affected is GESB14011-A with an expiration date of 12/15.
The recall was initiated due to complaints received regarding empty capsules. The agency has classified this recall as Class II, which indicates a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
The affected product was distributed nationwide. Consumers and healthcare providers should check their inventory for the specific lot number and expiration date listed above. If the product is found, it should be returned to the pharmacy or point of purchase for a refund or replacement, or disposed of according to local regulations.
The recalled product
- Product
- GABAPENTIN (GABAPENTIN)
- Brand
- GABAPENTIN
- Manufacturer
- Aurobindo Pharma USA Inc
- Category
- Drug — Prescription Medication
- Affected units
- 24,816
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: GESB14011-A
- Exp 12/15
UPCs (1)
- 316714662015
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · GABAPENTIN
- ModerateGabapentin blister packs recalled after unknown impurity exceeded specification
FDA (Drugs) · 2025-10-29
- ModerateGabapentin capsules recalled after stability testing found unknown impurity out of specification
FDA (Drugs) · 2025-10-29
- ModerateGabapentin capsule bags recalled because blister packaging was inadequately sealed
FDA (Drugs) · 2025-07-09
- ModerateGabapentin Capsules 100 mg recalled for defective blister packaging
FDA (Drugs) · 2025-07-09
- LowGabapentin Capsules 400 mg Recalled for Cross Contamination
FDA (Drugs) · 2025-04-16
Same manufacturer · Aurobindo Pharma USA Inc
See all →- ModerateDicyclomine Hydrochloride Capsules Recalled for Empty Capsules
FDA (Drugs) · 2026-08-12
- ModerateAmazon Basic Care Acetaminophen 325 mg Tablets Recalled Due to Discoloration
FDA (Drugs) · 2025-06-25
- HighPrescription drug recall: Aurobindo Nebivolol tablets contain excess nitrosamine impurity
FDA (Drugs) · 2024-12-25
- HighPrescription Cinacalcet Tablets Recalled for N-Nitroso Impurity
FDA (Drugs) · 2024-12-11
- HighFDA Recalls Cinacalcet 30mg Tablets for N-nitroso Impurity
FDA (Drugs) · 2024-12-11
Same hazard · quality control
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateDuoGlide Short-Term Dialysis Catheter recall due to deficient manufacturing
FDA (Devices) · 2026-07-08
- ModeratedirectCHECK whole blood control labeled with incorrect performance range
FDA (Devices) · 2026-06-24
- HighAmyloid plasma controls recalled over falsely elevated ratio results
FDA (Devices) · 2026-02-11
- HighpTau 217 plasma controls recalled over falsely elevated ratio results
FDA (Devices) · 2026-02-11